Open | $1.420 |
Close | $1.440 |
Volume / Avg. | 36.382K / 153.014K |
Day Range | 1.420 - 1.460 |
52 Wk Range | 0.980 - 2.090 |
Market Cap | $42.692M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 45 |
Short Interest | 0.43% |
Days to Cover | 1.8 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of NextCure (NASDAQ: NXTC) through any online brokerage.
Other companies in NextCure’s space includes: NKGen Biotech (NASDAQ:NKGN), Fortress Biotech (NASDAQ:FBIO), Estrella Immunopharma (NASDAQ:ESLA), Acurx Pharmaceuticals (NASDAQ:ACXP) and Cellectar Biosciences (NASDAQ:CLRB).
The latest price target for NextCure (NASDAQ: NXTC) was reported by Needham on Thursday, December 14, 2023. The analyst firm set a price target for 4.00 expecting NXTC to rise to within 12 months (a possible 161.44% upside). 4 analyst firms have reported ratings in the last year.
The stock price for NextCure (NASDAQ: NXTC) is $1.53 last updated March 13, 2024 at 6:12 PM EDT.
There are no upcoming dividends for NextCure.
NextCure’s Q1 earnings are confirmed for Thursday, May 2, 2024.
There is no upcoming split for NextCure.
NextCure is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.